JP2005525408A - アンフェナクまたはネパフェナクを用いる血管内皮増殖因子媒介性血管障害の処置方法 - Google Patents
アンフェナクまたはネパフェナクを用いる血管内皮増殖因子媒介性血管障害の処置方法 Download PDFInfo
- Publication number
- JP2005525408A JP2005525408A JP2004500853A JP2004500853A JP2005525408A JP 2005525408 A JP2005525408 A JP 2005525408A JP 2004500853 A JP2004500853 A JP 2004500853A JP 2004500853 A JP2004500853 A JP 2004500853A JP 2005525408 A JP2005525408 A JP 2005525408A
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- nepafenac
- retinal
- growth factor
- endothelial growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title claims abstract description 31
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title claims abstract description 31
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 21
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 229960001002 nepafenac Drugs 0.000 title claims abstract description 17
- 230000001404 mediated effect Effects 0.000 title claims abstract description 10
- SOYCMDCMZDHQFP-UHFFFAOYSA-N amfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=CC=C1 SOYCMDCMZDHQFP-UHFFFAOYSA-N 0.000 title description 6
- 229950008930 amfenac Drugs 0.000 title description 3
- 208000024248 Vascular System injury Diseases 0.000 title 1
- 208000012339 Vascular injury Diseases 0.000 title 1
- 208000019553 vascular disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 13
- 230000002207 retinal effect Effects 0.000 claims description 10
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 9
- 206010030113 Oedema Diseases 0.000 claims description 8
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 7
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 201000000159 corneal neovascularization Diseases 0.000 claims description 3
- 206010062198 microangiopathy Diseases 0.000 claims description 3
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 3
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 3
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 206010029113 Neovascularisation Diseases 0.000 description 9
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 5
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- -1 2-amino-3-benzoylphenylethyl alcohol Chemical compound 0.000 description 4
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 4
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- ALDSXDRDRWDASQ-UHFFFAOYSA-N 2-(3-benzoylphenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 ALDSXDRDRWDASQ-UHFFFAOYSA-N 0.000 description 3
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000010979 pH adjustment Methods 0.000 description 3
- 230000000649 photocoagulation Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- GTMSVJVBRIPWOZ-UHFFFAOYSA-N 2-[2-amino-3-(4-chlorobenzoyl)phenyl]acetic acid Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Cl)C=C1 GTMSVJVBRIPWOZ-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- YVKSMFUEDUPYIF-UHFFFAOYSA-N 3-oxo-2,3-diphenylpropanoic acid Chemical class C=1C=CC=CC=1C(C(=O)O)C(=O)C1=CC=CC=C1 YVKSMFUEDUPYIF-UHFFFAOYSA-N 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 101000585663 Homo sapiens Myocilin Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102100029839 Myocilin Human genes 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 206010028741 Nasal inflammation Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038886 Retinal oedema Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940112258 acular Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 201000011195 retinal edema Diseases 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229940061392 visudyne Drugs 0.000 description 1
- 229940063674 voltaren Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37742902P | 2002-05-03 | 2002-05-03 | |
| PCT/US2003/011769 WO2003092669A2 (en) | 2002-05-03 | 2003-04-16 | Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005525408A true JP2005525408A (ja) | 2005-08-25 |
| JP2005525408A5 JP2005525408A5 (enExample) | 2006-04-20 |
Family
ID=29401494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004500853A Pending JP2005525408A (ja) | 2002-05-03 | 2003-04-16 | アンフェナクまたはネパフェナクを用いる血管内皮増殖因子媒介性血管障害の処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20030207941A1 (enExample) |
| EP (1) | EP1507522A2 (enExample) |
| JP (1) | JP2005525408A (enExample) |
| KR (1) | KR20040101499A (enExample) |
| CN (1) | CN1649575A (enExample) |
| AU (1) | AU2003231730A1 (enExample) |
| BR (1) | BR0309747A (enExample) |
| CA (1) | CA2483275A1 (enExample) |
| MX (1) | MXPA04010132A (enExample) |
| PL (1) | PL373787A1 (enExample) |
| WO (1) | WO2003092669A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012062258A (ja) * | 2010-09-14 | 2012-03-29 | Oriza Yuka Kk | 血管新生抑制剤及びそれを用いた眼疾患予防・治療剤 |
| JP2018024689A (ja) * | 2011-09-16 | 2018-02-15 | フォーサイト・バイオセラピューティクス・インコーポレーテッド | 安定なポビドンヨード組成物 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060142236A1 (en) * | 1994-05-31 | 2006-06-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| WO2006056823A1 (en) * | 2004-11-26 | 2006-06-01 | Novagali Pharma Sa | Modulating retinal pigmented epithelium permeation by inhibiting or activating vegfr-1 |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| US20080293691A1 (en) * | 2005-11-29 | 2008-11-27 | Smithkline Beecham Corporation | Treatment Method |
| ES2686675T3 (es) * | 2013-03-29 | 2018-10-19 | Askat Inc. | Agente terapéutico para enfermedad ocular |
| EP3013790A1 (en) | 2013-06-27 | 2016-05-04 | Mylan Laboratories Ltd. | Process for the preparation of nepafenac |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE400966B (sv) * | 1975-08-13 | 1978-04-17 | Robins Co Inc A H | Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror |
| US4313949A (en) * | 1979-09-26 | 1982-02-02 | A. H. Robins Company, Inc. | Method of producing an inhibitory effect on blood platelet aggregation |
| US4254146A (en) * | 1979-10-18 | 1981-03-03 | A. H. Robins Company, Inc. | 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters |
| US4503073A (en) * | 1981-01-07 | 1985-03-05 | A. H. Robins Company, Incorporated | 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids |
| US4568695A (en) * | 1983-12-07 | 1986-02-04 | A. H. Robins Company, Incorporated | 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor |
| US4683242A (en) * | 1985-10-28 | 1987-07-28 | A. H. Robins Company, Incorporated | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters |
| CA1325382C (en) * | 1988-01-27 | 1993-12-21 | Takahiro Ogawa | Locally administrable therapeutic composition for inflammatory disease |
| US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
| US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
| WO2001015744A1 (en) * | 1999-08-31 | 2001-03-08 | The Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| AR030345A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes relacionados con angiogenesis |
| US6646003B2 (en) * | 2001-04-02 | 2003-11-11 | Alcon, Inc. | Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac |
-
2003
- 2003-04-16 CA CA002483275A patent/CA2483275A1/en not_active Abandoned
- 2003-04-16 CN CNA038094797A patent/CN1649575A/zh active Pending
- 2003-04-16 US US10/417,466 patent/US20030207941A1/en not_active Abandoned
- 2003-04-16 JP JP2004500853A patent/JP2005525408A/ja active Pending
- 2003-04-16 MX MXPA04010132A patent/MXPA04010132A/es unknown
- 2003-04-16 EP EP03747593A patent/EP1507522A2/en not_active Withdrawn
- 2003-04-16 US US10/511,414 patent/US20050143468A1/en not_active Abandoned
- 2003-04-16 AU AU2003231730A patent/AU2003231730A1/en not_active Abandoned
- 2003-04-16 BR BR0309747-1A patent/BR0309747A/pt not_active Application Discontinuation
- 2003-04-16 WO PCT/US2003/011769 patent/WO2003092669A2/en not_active Ceased
- 2003-04-16 PL PL03373787A patent/PL373787A1/xx not_active Application Discontinuation
- 2003-04-16 KR KR10-2004-7016542A patent/KR20040101499A/ko not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012062258A (ja) * | 2010-09-14 | 2012-03-29 | Oriza Yuka Kk | 血管新生抑制剤及びそれを用いた眼疾患予防・治療剤 |
| JP2018024689A (ja) * | 2011-09-16 | 2018-02-15 | フォーサイト・バイオセラピューティクス・インコーポレーテッド | 安定なポビドンヨード組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1507522A2 (en) | 2005-02-23 |
| WO2003092669A2 (en) | 2003-11-13 |
| BR0309747A (pt) | 2005-04-26 |
| US20050143468A1 (en) | 2005-06-30 |
| AU2003231730A1 (en) | 2003-11-17 |
| PL373787A1 (en) | 2005-09-19 |
| KR20040101499A (ko) | 2004-12-02 |
| CN1649575A (zh) | 2005-08-03 |
| CA2483275A1 (en) | 2003-11-13 |
| US20030207941A1 (en) | 2003-11-06 |
| MXPA04010132A (es) | 2005-01-25 |
| WO2003092669A3 (en) | 2004-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070071756A1 (en) | Delivery of an agent to ameliorate inflammation | |
| JP2012193214A (ja) | ベンゾイルフェニル酢酸を使用して、血管形成関連障害を処置するための方法 | |
| JP2011530496A (ja) | 眼新生血管形成症状の治療のためのソラフェニブを含む眼科用医薬組成物 | |
| Schechter | Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies | |
| Chen et al. | Nonsteroidal anti-inflammatory drugs for retinal neurodegenerative diseases | |
| US20110082200A1 (en) | 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses | |
| JP2005525408A (ja) | アンフェナクまたはネパフェナクを用いる血管内皮増殖因子媒介性血管障害の処置方法 | |
| US20090247638A1 (en) | Pharmaceutical use of cox-2-inhibitors in angiogenesis-mediated ocular disorders | |
| US20230338307A1 (en) | Prophylactic agent, ameliorating agent, and therapeutic agent for dry eye | |
| JPH026329B2 (enExample) | ||
| TW200800261A (en) | Compounds for the treatment of dryness of the ocular surface caused by photorefractive surgery | |
| US20040259765A1 (en) | Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis | |
| JP2020514347A (ja) | チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤 | |
| JP4150846B2 (ja) | ステロイドを有効成分とする網脈絡膜疾患治療剤 | |
| CN116270442B (zh) | 一种用于矫正近距离视力的眼用制剂 | |
| JP2012513393A (ja) | 眼の後区に、有効濃度の活性剤を送達するための、眼の局部に用いる溶液の組成物 | |
| JPH10203979A (ja) | チアプロフェン酸を含有する抗眼炎症剤 | |
| KR20200113221A (ko) | 다중 표적 억제제의 현탁액 조성물 | |
| US8207226B1 (en) | Use of FAAH antagonists for treating dry eye and ocular pain | |
| JP7197112B2 (ja) | 水泡性角膜症治療用医薬組成物 | |
| Theodosiadis et al. | Preservative-free versus preserved latanoprost eye drops for reducing intraocular pressure: a non-inferiority phase III randomized, multi-center, single-blind, parallel-group controlled trial | |
| JP2009517375A (ja) | 眼の疾患の治療 | |
| Sampaolesi et al. | Medical Therapy in Glaucoma | |
| Williamson et al. | 14 Medical Therapy for Glaucoma | |
| ZA200509532B (en) | Formulations or non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090729 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100114 |